DK1507547T3 - Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet - Google Patents

Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet

Info

Publication number
DK1507547T3
DK1507547T3 DK03711550.8T DK03711550T DK1507547T3 DK 1507547 T3 DK1507547 T3 DK 1507547T3 DK 03711550 T DK03711550 T DK 03711550T DK 1507547 T3 DK1507547 T3 DK 1507547T3
Authority
DK
Denmark
Prior art keywords
plasminogen activator
upa
tpa
peptides
regulation
Prior art date
Application number
DK03711550.8T
Other languages
English (en)
Inventor
Abd-Al-Roof Higazi
Original Assignee
Thrombotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/020077 external-priority patent/WO2003006042A1/en
Application filed by Thrombotech Ltd filed Critical Thrombotech Ltd
Application granted granted Critical
Publication of DK1507547T3 publication Critical patent/DK1507547T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
DK03711550.8T 2002-05-08 2003-03-12 Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet DK1507547T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/063,046 US20030211095A1 (en) 2002-05-08 2002-05-08 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
PCT/US2002/020077 WO2003006042A1 (en) 2001-07-10 2002-06-24 Peptide for regulation of tissue plasminogen activator
PCT/US2003/007683 WO2003095476A2 (en) 2002-05-08 2003-03-12 PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Publications (1)

Publication Number Publication Date
DK1507547T3 true DK1507547T3 (da) 2012-01-16

Family

ID=29399060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03711550.8T DK1507547T3 (da) 2002-05-08 2003-03-12 Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet

Country Status (10)

Country Link
US (1) US20030211095A1 (da)
EP (1) EP1507547B1 (da)
JP (1) JP2006502096A (da)
AT (1) ATE525081T1 (da)
AU (1) AU2003213856B2 (da)
CA (1) CA2488968C (da)
DK (1) DK1507547T3 (da)
ES (1) ES2373713T3 (da)
IL (1) IL165066A (da)
WO (1) WO2003095476A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263351A1 (en) * 2002-12-31 2006-11-23 The General Hospital Corporation Methods and compositions for protection against thrombolysis associated reperfusion injury
JP5421257B2 (ja) * 2007-07-24 2014-02-19 ディー−ファーム リミテッド プラスミノーゲン活性化因子阻害物質１由来のペプチドおよびその使用
KR101712208B1 (ko) 2008-01-09 2017-03-03 인트렉손 코포레이션 Ｐａｉ―１ 작용의 치료학적 억제제 및 이의 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558010A (en) * 1980-04-03 1985-12-10 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
US5130143A (en) * 1988-11-04 1992-07-14 The Research Foundation Of State University Of New York Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6150332A (en) * 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
AU739373B2 (en) * 1997-10-17 2001-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
WO2003006042A1 (en) * 2001-07-10 2003-01-23 Thrombotech Ltd. Peptide for regulation of tissue plasminogen activator

Also Published As

Publication number Publication date
AU2003213856B2 (en) 2008-10-16
EP1507547B1 (en) 2011-09-21
CA2488968A1 (en) 2003-11-20
WO2003095476A3 (en) 2004-04-01
IL165066A0 (en) 2005-12-18
CA2488968C (en) 2013-10-29
EP1507547A2 (en) 2005-02-23
WO2003095476A2 (en) 2003-11-20
IL165066A (en) 2011-03-31
AU2003213856A1 (en) 2003-11-11
ATE525081T1 (de) 2011-10-15
JP2006502096A (ja) 2006-01-19
EP1507547A4 (en) 2007-03-14
US20030211095A1 (en) 2003-11-13
ES2373713T3 (es) 2012-02-08

Similar Documents

Publication Publication Date Title
Cubellis et al. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1.
ATE299493T1 (de) N-cyanomethylamide als protease inhibitoren
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
ATE182336T1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
DK1456366T3 (da) Ny alkalisk protease fra Bacillus gibsonii (DSM 14393) og vaske- og ren-gøringsmidler indeholdende denne nye alkaliske protease
ES2031826T3 (es) Procedimiento para producir nuevos peptidos activadores del plasminogeno.
DK1244794T3 (da) Mutant-aprE-promotor
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
TW200733970A (en) Recombinantly modified plasmin
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
ATE555119T1 (de) Expression von proteaseinhibitoren und varianten davon in filamentösen pilzen
DK1507547T3 (da) Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet
Wiederanders The function of propeptide domains of cysteine proteinases
DK1485345T3 (da) Urokinaseinhibitorer, deres fremstilling og anvendelse
SI1997510T1 (sl) Ne neurotoksiäśni plasminogen aktivirajoäśi faktroji za obdelavo moĺ˝ganske kapi
ATE345816T1 (de) Antithrombose agenzien
WO2004099410A3 (en) Compound and method for regulating plasminogen activation and cell migration
Mohanam et al. Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
PT768892E (pt) Composicao trombolitica
DE60034434D1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
WO2006079929A3 (en) Therapeutic peptides derived from urokinase plasminogen activator receptor
DE10342784A1 (de) Medizinisch anwendbare Peptide